What is the mechanism of action of sorafenib? How does it work against cancer cells?

Sorafenib is a multi-target targeted therapy drug that is widely used to treat various types of cancer, especially liver cancer, kidney cancer and some advanced thyroid cancers. It exerts anti-cancer effects by interfering with multiple signaling pathways related to tumor cell growth, angiogenesis and metastasis. The mechanism of action of sorafenib is mainly through inhibiting the RAF/MEK/ERK pathway, VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor) and other receptors, thereby inhibiting the proliferation, angiogenesis and metastasis of tumor cells.

1. InhibitionRAF/MEK/ERKpathway

The RAF/MEK/ERK pathway is one of the important signaling pathways for cell proliferation and survival. In many cancers, activation of the RAF/MEK/ERK pathway promotes cancer cell proliferation and survival. Sorafenib inhibits the kinase activity of RAF protein and blocks further activation of this signaling pathway, thereby reducing the proliferation of cancer cells. RAFThe inhibitory effect of protein can not only slow down the growth of tumor cells, but also reduce the invasiveness and metastasis ability of tumors. In addition, MEK and ERK are also key kinases in this pathway. Sorafenib affects RAF The inhibition of pan> indirectly reduces the activities of MEK and ERK, thereby further inhibiting the proliferation and migration of cancer cells.

2. Inhibit vascular endothelial growth factor receptor (VEGFR)

Angiogenesis, the generation of new blood vessels, is one of the key factors in tumor growth and metastasis. Tumor cells usually promote the formation of new blood vessels by secreting vascular endothelial growth factor (VEGF), which provides necessary nutrients and oxygen to the tumor to support its continued growth and spread. By inhibiting the activity of VEGFR, sorafenib reduces the angiogenesis mediated by VEGF and prevents the vascularization process of tumors. This inhibitory effect effectively limits the supply of nutrients and oxygen required for tumor growth, leaving tumor cells in a hypoxic state, thereby inhibiting their further growth.

3.Inhibits platelet-derived growth factor receptor (PDGFR)

In addition to VEGFR, PDGFR (platelet-derived growth factor receptor) is also one of the important receptors in the tumor microenvironment. PDGF signaling pathway plays an important role in tumor angiogenesis, tumor cell migration and drug resistance development. By inhibiting the kinase activity of PDGFR, sorafenib reduces the growth signals obtained by tumor cells through this pathway, thereby inhibiting tumor angiogenesis, invasion and metastasis. In addition, inhibition of PDGFR can also change the tumor microenvironment, making it more unfavorable for the survival and spread of tumor cells.

4. Effects on tumor cell proliferation and apoptosis

Sorafenib also works by regulating the proliferation and apoptosis of tumor cells. By inhibiting multiple kinases in tumor cells, sorafenib not only slows down the proliferation of tumor cells, but also promotes tumor cell apoptosis. In some cancer types, sorafenib can cause cells to enter programmed death by inducing a stress response in cancer cells. In this way, sorafenib has a direct killing effect on tumor cells and reduces the survival of tumor cells.

In summary, sorafenib exerts its anti-cancer effects through multiple pathways. It not only inhibits the proliferation of tumor cells by inhibiting the RAF/MEK/ERK pathway, but also inhibits tumor angiogenesis and metastasis by blocking the VEGFR and PDGFR signaling pathways. In addition, sorafenib can further reduce tumor burden by inducing apoptosis of tumor cells. These effects make sorafenib an effective drug for the treatment of liver cancer, kidney cancer, thyroid cancer and other tumors, and it is widely used clinically.

Reference materials:https://www.nexavar.com/